The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT).
 
David Hui
Consulting or Advisory Role - Eton Pharmaceuticals
 
Ishwaria M. Subbiah
Consulting or Advisory Role - MedImmune (I)
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I)
Travel, Accommodations, Expenses - AstraZeneca
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Jennifer Ellefson
No Relationships to Disclose
 
Josue Becerra
No Relationships to Disclose
 
Vera J De la Cruz
No Relationships to Disclose
 
Diana L. Urbauer
No Relationships to Disclose
 
Sanjay Shete
Stock and Other Ownership Interests - 23andMe
 
Eduardo Bruera
Research Funding - PharmaCann (Inst)